NCT07836673Not yet recruiting
Pre-Exercise Whey and Pea Protein in Adolescents With Type 1 Diabetes
Effects of Pre-Exercise Whey and Pea Protein Intake on Glycemic Responses and Postprandial Appetite During and After Moderate-Intensity Aerobic Exercise in Jordanian Adolescents With Type 1 Diabetes: A Randomized Crossover Trial.
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether drinking whey protein or pea protein before exercise affects blood sugar levels and appetite in adolescents with type 1 diabetes. The study will also compare two different amounts of each type of protein. The main questions this study aims to answer are: * Does drinking whey or pea protein before exercise affect blood sugar levels during and after moderate-intensity exercise? * Does the amount of protein consumed before exercise affect blood sugar levels? * Does whey or pea protein affect feelings of hunger, fullness, and satiety after exercise? Researchers will compare four conditions: a low and moderate amount of whey protein and a low and moderate amount of pea protein. Each participant will complete all four conditions on separate study visits, allowing researchers to compare the effects within the same person. Participants will: * Drink a protein beverage 45 min before exercise. * Complete 45 min moderate-intensity aerobic exercise under supervision. * Wear a continuous glucose monitor to measure blood sugar levels during and after exercise. * Report their feelings of hunger, fullness, and satiety at several times during the study. * Follow the same general food, physical activity, and diabetes management instructions before each study visit. The study may help researchers understand whether the type and amount of protein consumed before exercise can help manage blood sugar levels and appetite around exercise in adolescents with type 1 diabetes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Feb 2027
- Lead sponsor
- University of Jordan
- Diseases
- Type 1 diabetes
- NCT number
- NCT07836673
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Oct 2026 to the primary completion date, Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical comorbidities (celiac disease and thyroid disease),
- Diabetes complications or gastroparesis,
- milk protein allergy or eating disorders,
- Unable to exercise safely (physical limitations, intellectual disability, autism, mental health conditions)
Lab values
- T1D duration \< 1 year or HbA1c ≥10%
Age
- Age: \<12 or \> 18 years
- BMI -for Age- z-score \< -2 or \> +2
Other
- severe hypo/ diabetic ketoacidosis in the past 3 months
- Not using/willing/able to use CGM
- Using once daily/mixed insulin regimens
Who the study is looking for
- Male and female adolescents with T1D
- Age: 12-18 years
- T1D duration ≥ 1 year and HbA1c \<10%
- BMI-for Age- z-score between -2 and +2
- Able to complete 45 min moderate-intensity aerobic exercise
- Using CGM or willing / able to wear study CGM
- Using multiple daily injections
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.